Skip to main content
. 2013 Apr 12;54(4):2624–2633. doi: 10.1167/iovs.13-11803

Figure 2.

Figure 2

PEDF-mediated RGC neuroprotection is dose-dependent in vivo. (A) Representative images show FG-labelled RGC after intravitreal injection of 0, 0.2, 0.5, 1, 1.5, and 2 μg/μL of PEDF at 21 days after ONC. (B) The number of FG+ RGC at the different doses of PEDF and in intact controls. Scale bar: 50 μm (A).